Celebrex Proposed “Black Box” Could Be Removed With Safety Data – Cmte.
Executive Summary
Pfizer should have the opportunity to get a proposed Celebrex COX-2 class cardiovascular "black box" warning removed from labeling if the company is able to demonstrate safety in post-marketing safety studies, an FDA advisory committee said
You may also be interested in...
Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits?
Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk